ABPI response to Board of Trade report on Life Sciences

ABPI response to the UK Board of Trade’s latest report on the UK life sciences published today by the Board of Trade. 

“This report underlines the importance of the life sciences sector to the UK’s strategy for exports, trade and economic growth. ABPI Executive Director of International Policy, Claire Machin

Responding to the UK Board of Trade’s latest report on the UK life sciences, ABPI Executive Director of International Policy, Claire Machin said:

“This report underlines the importance of the life sciences sector to the UK’s strategy for exports, trade and economic growth. 

“However, it also captures worrying signs that we may be falling behind our global competitors.  The manufacture of life science products has seen a rapid decline in recent years, with the UK falling from 4th to 98th place in overall trade balance for pharmaceuticals since 2010.

“This decline demonstrates the urgent need to improve the UK's offer to global life sciences companies using the UK’s trade policy strategy, as one tool to help reverse this trend and further drive the UK’s economic recovery.”

You can find the Board of Trade report here.   

TAGS
  • Trade
  • Life Sciences

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.